Merrion Pharmaceuticals (www.merrionpharma.com) is a publicly listed product development company focused on delivering innovation to the market by working on our own products and partnering to develop strategic products. Established in 2003, Merrion are engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection.
Merrion Pharmaceutical's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. This can provide substantial benefits in patient convenience and safety, and might also provide enhanced drug efficacy. Merrion utilises its technology to develop new oral drugs in two ways; it develops its own proprietary drugs using GIPET and partners with other pharmaceutical companies in developing oral GIPET formulations of their products.
Merrion has agreements with several pharmaceutical companies. Merrion has two license agreements with Novo Nordisk A/S to develop and commercialise oral forms of Novo Nordisk’s Insulin and GLP-1 using Merrion’s proprietary GIPET technology. In addition, Merrion has a collaboration and option agreement with Novo Nordisk for an undisclosed compound. Merrion also has an oral drug delivery research collaborative program with Ferring Pharmaceuticals, an undisclosed ‘top ten’ pharma company, Rebel Pharmaceuticals and other non disclosed pharma companies.
Merrion Pharmaceuticals is based in Dublin, in a state of the art purpose built facility which allows speed of development and reduced risk in taking ideas from conception to final phase II formulation in our own cGMP facilities. Merrion also has operations in Wilmington, North Carolina.
Merrion is listed on the Irish Stock Exchang(ESM) under the symbol MERR.
Merrion Pharmaceuticals in the News